Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5770
Title: Development of reversible posterior leukoencephalopathy syndrome after cyclophosphamide treatment in a patient with lupus nephritis
Authors: Yildiz, S.
Güçlü, A.
Degirmenci, E.
Kiroglu, Y.
Yalçin, N.
Çobankara, V.
Topaloglu, M.
Erürker, Muammer
Keywords: Cyclophosphamide
Lupus nephritis
Reversible posterior leucoencephalopathy syndrome
Abstract: Renal involvement in systemic lupus erythematosus is a frequent and serious complication that significantly increases morbidity and mortality. Despite all studies and usage of new drugs, treatment of lupus nephritis continues to be a problem. Diffuse proliferative lupus nephritis has a poor prognosis and aggressive treatment must be undertaken. Cyclophosphamide is commonly used in treatment despite its side effects. Reversible posterior leucoencephalopathy syndrome is a clinico-radiological syndrome manifested by blood pressure elevation, headache, visual disturbances, confusion, seizures and sometimes focal neurological signs that can develop due to usage of cytotoxic drugs. We present a case of lupus nephritis in which reversible posterior leucoencephalopathy syndrome developed after intravenous cyclophosphamide administration and recovered spontaneously by symptomatic treatment in this article.
URI: https://hdl.handle.net/11499/5770
https://doi.org/10.5262/tndt.2011.1001.19
ISSN: 1300-7718
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
bd55f36b-020f-4bac-adcf-f97aa6e06994.pdf321.74 kBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

38
checked on May 27, 2024

Download(s)

2
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.